CN

CN

News

Company News Industry News

Company News

MediLink Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of YL217

July 2, 2025 – MediLink Therapeutics, a clinical-stage biotechnology company, today announced that the first patient has been enrolled and dosed in China in the Global Phase I clinical trial of YL217. YL217 is a CDH17-targeting antibody-drug conjugate (ADC) based on MediLink’s proprietary TMALIN® technology platform.

2025-07-03

MediLinks Appoints Dr. Weichang Zhou as Chief Technology Officer

2025-07-01

MediLink Announces YL201 Granted Breakthrough Therapy Designation by FDA

June 23, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to YL201 for the treatment of small cell lung cancer (SCLC). YL201 is an investigational B7H3-targeted antibody drug conjugate (ADC) developed based on MediLink’s proprietary TMALIN® (Tumor Microenvironment Activable LINker) technology platform.

2025-06-24

MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits

The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024. Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results. In extensive-stage SCLC patients, ORR was 68.1% and mPFS was 6.2 months.

2024-09-14Learn more

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech

MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink’s TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.

2024-05-27Learn more

MediLink announces the first patient dosed with YL211

SUZHOU, CHINA, May 2, 2024 -- MediLink Therapeutics (“MediLink”) today announced that the first patient has been successfully dosed with YL211 in a phase I study in the US. MediLink and Roche had previously entered into a worldwide collaboration and license agreement on YL211. Following the execution of this agreement, the Investigational New Drug (IND) application for YL211 has been cleared by the U.S. Food and Drug Administration (FDA), and a phase I study to assess the safety, pharmacokinetics and preliminary efficacy of YL211 in patients with advanced solid tumors has been initiated subsequently.

2024-05-02Learn more

MediLink Therapeutics presents its platform and pipeline progress at AACR 2024

MediLink Therapeutics will present its next-generation TMALIN ("Tumor Microenvironment Activable LINker-payload”) platform and preclinical results of YL205, a novel antibody drug conjugate targeting NaPi2b, at the American Association for Cancer Research 2024 meeting (AACR 2024), which takes place April 5-10 in San Diego, United States. Presented studies are as follows:

2024-04-07Learn more

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology

SUZHOU, CHINA, January 2nd, 2024 -- MediLink Therapeutics (“MediLink”), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.

2024-01-02Learn more

MediLinks Appoints Jason (Jia) Li as Chief Financial Officer

January 1st, 2024, MediLink Therapeutics solemnly announced the official appointment of Mr. Jason (Jia) Li as the company's chief financial officer (CFO). Mr. Li will report to Dr. Tongtong (Tony) Xue, Chairman and CEO of the company, and will be responsible for the overall financial planning and management, corporate finance and IPO, development strategy and other financial work, so as to promote the internationalization process and further steady development of the company's business, and address more unmet clinical needs.

2024-01-01Learn more
1 2 3 4 5 6